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Abstract: Advances in the understanding of the biology of renal cell carcinoma have led to 
recent approval of several new agents including drugs that target vascular endothelial growth 
factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular 
tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and 
subsequently improvement in progression free survival in phase III renal cancer trials. We 
review the unique side effects of sunitinib therapy with emphasis on establishing effective patient 
education for anticipation and early management of therapy-related side effects.
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Introduction
Kidney cancer accounts for 2% of all adult cancers.1,2 The median age of diagnosis is 
65 years of age, with a slightly less than 2:1 male:female predominance. Although the 
classical clinical presentation included the triad of ﬂ  ank pain, abdominal mass, and 
hematuria, in the current era, most renal masses are detected as incidental ﬁ  ndings on 
radiological imaging obtained for unrelated reasons. Approximately 30% of patients 
with renal cell carcinomas (RCC) are metastatic at the time of diagnosis.3 Forty percent 
of localized renal cell cancers at diagnosis become recurrent.4 The estimated 5-year 
survival rate of metastatic RCC (mRCC) is less than 30%. Risk factors associated 
with the incidence of kidney cancer include polycystic kidney disease, cysts occurring 
with hemodialysis, obesity, smoking, and hypertension.5 Certain genetic syndromes 
such as von Hippel-Lindau (VHL) have increased incidence of renal cancer. Clear 
cell RCC is the most common form of kidney cancer accounting for more than 85% 
of all kidney cancer.6
Historically, RCC has been viewed as a therapy-resistant cancer.3 Until the 
recent development of targeted agents, the therapeutic paradigm consisted of 
biological response modiﬁ  er therapy including a variety of doses, combinations 
and schedules of interleukin-2 and interferon-alpha. The development of new and 
active agents followed scientiﬁ  c advances in the understanding of renal cancer 
biology. Dramatic improvements in renal cell cancer treatment and outcomes 
have occurred over the past few years. This progress has been driven in large part 
due to the improvement in understanding of the biology of RCC. Identiﬁ  cation 
of the VHL gene as a tumor suppressor gene, whose inactivation by mutation or 
methylation leads to the formation of RCC, has elucidated the biology of sporadic 
RCCs.7 The protein product of the VHL functions in its intracellular pathway as a 
tumor suppressor by targeting hypoxia-inducible factor for proteosomal destruction. 
Without VHL, in the presence of uninhibited hypoxia-inducible factor, the cascade 
of intranuclear events leads to transcription of a number of genes, including vascular OncoTargets and Therapy 2009:2 52
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endothelium growth factor (VEGF) and platelet-derived 
growth factor (PDGF), leading to increased growth and 
vascular angiogenesis.8
Efforts to target the unique molecular derangements 
have focused on therapy which can interrupt these tumoro-
genic pathways. One multitarget agent in this emerging 
antineoplastic category includes sunitinib, which acts as an 
intracellular tyrosine kinase inhibitor (TKI) of multiple fac-
tors, including the intracellular domain of VEGF receptor 
(VEGFR-1, VEGFR-2), PDGF receptor (PDGFR-alpha and 
PDGF-beta), fetal liver tyrosine kinase receptor 3 (FLT3), 
and KIT (stem-cell factor receptor).9,10
The initial phase I trial of sunitinib was conducted in a 
dose-escalating fashion using a 4 weeks on drug followed 
by 2 weeks off drug regimen.11 The time off period was ini-
tially chosen to allow for recovery from potential toxicities 
of bone marrow suppression or adrenal suppression which 
were seen in preclinical animal studies. Dosing recommen-
dations based on safety and toxicity were determined by 
phase I experience of 28 patients which used various dosing 
schedules and established a starting dose of 50 mg qd for 
28 days followed by a 14-day period off drug. Dose limit-
ing toxicities included fatigue, hypertension, and hand-foot 
syndrome (HFS).11 With this regimen, mucositis, peripheral 
edema, thrombocytopenia and neutropenia represented the 
majority of side effects. Asthenia and laboratory toxicities 
including thrombocytopenia and neutropenia improved after 
2-week rest period.
Two phase II trials of mRCC patients demonstrated 
partial responses to sunitinib in patients who had failed prior 
cytokine therapy. In the ﬁ  rst phase II trial of 63 patients, 40% 
of patients achieved partial responses with a median time 
to progression of 8.7 months.12 A second phase II trial con-
ducted of 106 clear cell mRCC patients demonstrated a partial 
response in 34% of patients with a median progression-free 
survival of 8.3 months.13 A pivotal phase III trial of previously 
untreated patients with RCC comparing sunitinib with inter-
feron-alpha demonstrated increased progression free survival 
of 11 vs 5 months (p  0.001) and objective response rate 
31% vs 6% (p  0.001).14 At the time of analysis and pub-
lication, the original results of the phase III trial comparing 
sunitinib with interferon, the median duration of treatment 
was 6 months; an updated analysis of this data, after a median 
sunitinib treatment duration of 11 months, demonstrated an 
overall response rate of 47% (95% CI: 42, 52) for sunitinib vs 
12% (95% CI: 9, 16) for interferon-alpha (p  0.000001).15
Prospective data of side effects of sunitinib come primar-
ily from the experience of these two phase II trials12,13 and 
one phase III trial (Table 1).14 Most toxicities were grade 1 
or 2, with common adverse events including fatigue, diar-
rhea, neutropenia and anemia, gastrointestinal, skin and 
hair, and cardiac. Diarrhea was the most common side 
effect, with 53% of patients having any grade of diarrhea, 
of which 5% were grade 3 and there were no grade 4 toxici-
ties. Overall, in this phase III study 38% of patients had a 
dose interruption of therapy and 32% of patients required 
Table 1 Selected adverse events and laboratory abnormalities from phase II and III studies
Adverse event Phase III study14 N = 375 Phase II study12* N = 63 Phase II study13* N = 106
Grades 1–4 Grades 3/4 Grades 2–4 Grades 3/4 Grades 2–4 Grades 3/4
Signs and symptoms
 Diarrhea 53% 5% 24% 3% 20% 3%
 Fatigue 51% 7% 38% 11% 28% 11%
 Nausea 44% 3% 19% 3% 13% 0%
 Stomatitis 25% 1% 19% 2% 13% 5%
 Vomiting 24% 4% 13% 3% 10% 0%
 Hypertension 24% 8% 5% 2% 16% 6%
 Hand-foot  syndrome 20% 5% 8% 2% 15% 7%
Laboratory abnormality
 Neutropenia 72% 12% 45% 13% 42% 16%
 Anemia 71% 4% 37% 10% 26% 6%
  Increased creatinine 66% 1% 14% 0% Not reported Not reported
 Thrombocytopenia 65% 8% 18% 0% 21% 6%
*Grade 1 toxicities not reported in study.
Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0.40OncoTargets and Therapy 2009:2 53
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dose reduction; however, only 10% discontinued drug due 
to adverse events.
Criteria for entry into the phase III trial which com-
pared sunitinib with interferon-alpha included previously 
untreated patients with histology of clear cell component, 
Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 or 1, no prior brain metastases, no uncontrolled 
hypertension, and no cardiac events the 12 months prior to 
entry into the study.14 However, subsequently after regula-
tory approval in the United States, the use of sunitinib has 
expanded to patients with prior therapy and unselected 
patients with unfavorable risk factors, as well as patients 
who have not undergone nephrectomy. An expanded access 
trial of approximately 4000 patients included patients with 
prior cytokine treatment (71%), ECOG score of 2 or better, 
7.5% of patients had prior brain metastases, and 13% did 
not have clear cell histology.16 Notably, with increased time 
on sunitinib, 69% of patients who had been on treatment 
for more than 6 months experienced adverse events, com-
pared with 25% of patients who were on sunitinib for less 
than 6 months. Grade 3 or 4 events which occurred in 39% 
of patients on sunitinib for longer than 6 months included 
nausea (1%), mucosal inﬂ  ammation (2%), diarrhea (4%), 
fatigue (6%), thrombocytopenia (6%), and neutropenia 
(5%). The incidence of grade 3 or 4 cardiac adverse events 
was less than 1% which was not increased over time in 
extended use of sunitinib, demonstrating no increased car-
diac toxicity over extended time periods. In this analysis, 
8% of patients who were on sunitnib longer than 6 months 
discontinued therapy due to adverse events compared with 
13% of patients on therapy less than 6 months.16 In a separate 
analysis of the 82 evaluated patients, 43% of sunitinib-treated 
RCC patients required dose reductions for treatment-related 
adverse events.17 Stomatitis, fatigue and HFS were the most 
frequent reasons for dose reductions. There was a correlation 
between increased adverse events and low body surface area, 
increased age, and female gender in the 49% of  patients who 
underwent dose reductions or discontinuation.17 Further pro-
spective evaluation of these and other patient characteristics 
predictive of toxicity is needed.
Adequate drug exposure is required to optimize sunitinib 
anti-tumor effect. Pharmacokinetic analyses demonstrate that 
sunitinib plasma concentrations correlate signiﬁ  cantly with 
the probability of a partial response and time to progression 
in cytokine refractory patients.18 Since increased exposure 
to sunitinib is associated with improved clinical efﬁ  cacy, 
the therapeutic goal should be to administer sunitinib at the 
highest tolerated dose for each patient, and to minimize dose 
delays, reductions, or discontinuation secondary to treatment 
related adverse side effects. This is best done through effec-
tive communication, early recognition of anticipated side 
effects, early intervention, and ongoing assessment of man-
agement strategies. The remainder of this article will focus 
on speciﬁ  c toxicities unique to sunitinib with emphasis on the 
incidence, purported mechanism when known, management 
and surveillance of each side effect.
Based on the phase II and III clinical trials, the recom-
mended starting dose of sunitinib is 50 mg orally once daily 
for 28 days followed by a 14 day drug rest. The capsules 
are manufactured in strengths of 50, 25, and 12.5 mg. Dose 
limiting toxicities should result in initial dose reductions by 
12.5 mg to 37.5 mg and then 25 mg daily. Dose reductions 
of sunitinib less than 25 mg daily may result in lower serum 
levels which may reduce therapeutic efﬁ  cacy for the majority 
of patients and alternate therapy should be considered.11,18
Prior to initiating treatment, a focused review of past and 
current medical conditions should be conducted with empha-
sis on evaluation and optimization of clinical parameters 
which may be affected by sunitinib-related toxicities. These 
include aggressively managing uncontrolled hypertension, 
assessing for nutritional deﬁ  ciencies, and detecting undiag-
nosed hypothyroidism. An evaluation of mucosal and skin 
surfaces with emphasis on foot examination is recommended. 
Consultation with podiatry or dermatology should be con-
sidered to treat pre-existing dermal pathology and optimize 
foot health prior to initiation of therapy. A multidisciplinary 
approach is recommended to provide an environment to 
facilitate good communication strategies with patients of the 
understanding, awareness, prevention, early detection, and 
management of side effects of sunitinib.
Drug interactions
Sunitinib is metabolized in the liver by cytochrome P450 
(CYP3A4) pathway; thus, drugs that affect the CYP3A4 path-
way may alter the metabolism of sunitinib and affect serum 
levels (Table 2). Caution should be used when sunitinib is 
administered in patients also receiving CYP3A4 inhibitors, 
as this may result in increased serum concentrations of both 
drugs. Conversely, coadministration with CYP3A4 inducers 
may lead to lower sunitinib levels and potentially decrease 
the efﬁ  cacy and response of tumor to therapy. A thorough 
drug history should include medication list, prescription 
and nonprescription, and herbal remedies. St. John’s Wort, 
a common herbal remedy, is a CYP3A4 inducer, while 
grapefruit-containing products inhibit the CYP3A4 enzyme. 
Patients should be instructed to notify their oncology health OncoTargets and Therapy 2009:2 54
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care team of any new medications to minimize the potential 
for serious drug interactions. Coumadin is metabolized 
in the liver primarily by the P450 CYP2C9 cytochrome; 
however, a minor metabolic pathway involves metabolism 
via the CYP3A4 pathway, and thus theoretically, there may 
be alterations in warfarin metabolism.19 Patients on warfarin, 
or in whom warfarin is initiated while on sunitinib, should 
have close monitoring of their anticoagulation therapy with 
INR. Additionally, the treatment regimen of 4 weeks on 
therapy and 2 weeks off sunitinib each cycle may result in 
variable warfarin metabolism resulting in ﬂ  uctuations of INR 
which should be anticipated and coumadin dosing should be 
individualized and adjusted accordingly.
Fatigue
Review of the available studies and clinical experience iden-
tiﬁ  es fatigue as one of the most common toxicities sunitinib, 
but the degree of fatigue and its effect on quality of life is 
variable. Many patients carry on their normal activities of 
daily living and maintain similar activity schedules, while 
others experience fatigue and asthenia which ultimately 
are dose limiting. Management of fatigue is primarily 
supportive; however, it is important to identify correctable 
causes which may also contribute to fatigue, such as anemia 
and hypothyroidism. The presence of fatigue may also be 
a manifestation of psychosocial issues. Patients should 
be assessed for signs and symptoms of clinical depression 
and appropriate treatment measures should be introduced to 
optimize emotional and social support with pharmacologic 
treatment introduced when necessary. Identiﬁ  cation and 
appropriate management of pain can help reduce debility. 
Ensuring proper nutrition and prevention of malnutrition, 
anorexia, and dehydration may also help reduce fatigue. 
Despite these interventions, dose reductions or treatment 
delays may be needed to allow patients to recover their 
quality of life and performance status.
Hypothyroidism
Multiple studies have identiﬁ  ed thyroid dysfunction as a 
toxicity of sunitinib.20–22 In a retrospective review of the 
records of 66 patients receiving sunitinib for RCC, 85% of 
patients who were initially euthyroid developed one or more 
abnormal thyroid function tests.20 Thirty percent of patients 
were initiated on treatment for biochemical and clinical hypo-
thyroidism resulting in a biochemical resolution of thyroid 
function abnormalities.
Subsequent prospective evaluation of 59 patients under-
going treatment with sunitinib for RCC or gastrointestinal 
stromal tumor determined that 27% of patients developed 
subclinical or clinical hypothyroidism.21 The percentage 
of RCC patients requiring treatment for hypothyroidism 
was 33%. The need for treatment was deﬁ  ned as persistent 
TSH greater than 10 mU/liter occurring on day one for two 
consecutive cycles and and typical symptoms of hypothy-
roidism. The median time to abnormal TSH for the RCC 
patients treated with sunitnib was 4 weeks, with a range of 
2 to 22 months. Interestingly, most patients showed a pattern 
of elevated TSH level on day 28 of treatment cycle with a 
trend towards normalization 2 weeks later on the ﬁ  rst day of 
the next treatment cycle after 2 weeks off sunitinib. Based 
on these observations and studies, the occurrence of thyroid 
abnormalities is high enough to warrant baseline thyroid 
function studies prior to initiation of sunitinib and every 
2 cycles and thereafter when clinical symptoms develop. 
Clinical symptoms of hypothyroidism include fatigue, 
weakness, muscle aches and cramps, cold intolerance, bra-
dycardia, depression, decreased deep tendon reﬂ  exes and 
myxedematous changes. Thyroid hormone replacement 
is indicated for severe biochemical abnormalities, such 
as TSH above 10 mU/liter, and/or if clinical symptoms of 
hypothyroidism develop. Mild elevations of TSH without 
Table 2 Selected drug interactions41
CYP3A4 Inhibitors (may raise sunitinib levels)
 Atanzanavir
 Clarithromycin
 Grapefruit
 Indinavir
 Itraconazole
 Ketoconazole
 Nefazodone
 Nelﬁ  navir
 Ritonavir
 Saquinavir
 Telithromycin
 Voriconazole
CYP3A4 Inducers (may lower sunitinib levels)
 Carbamazepine
 Dexamethasone
 Phenobarbital
 Phenytoin
 Rifabutin
 Rifampin
 Rifapentin
 St  John’s  WortOncoTargets and Therapy 2009:2 55
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other biochemical or clinical abnormalities may warrant 
only continued monitoring.
Cardiovascular side effects
VEGF inhibitors appear to have a class effect on the car-
diovascular system including hypertension and cardiac 
toxicity. While the precise mechanism is not clear, hypoth-
eses include pressor stimulation, increased extracellular 
volume, decreased vascular compliance, increased vascular 
resistance, endothelial dysfunction and altered nitrous oxide 
metabolism.23 In vitro evaluations of mice, rat, and human 
cardiomyocytes and coronary artery smooth muscle cells 
treated with sunitinib demonstrated toxicities, including 
myoﬁ  brillar disorganization, mitochondrial injury, and altera-
tion of intracellular signaling pathways.24 Hypoxia inducible 
factor-1 related products are involved in myocardial response 
to ischemia, cardiac remodeling and revascularization, and 
thus inhibition of these products might be expected to hinder 
normal cardiac repair mechanisms.25,26
With increased clinical experience and widespread use 
of sunitinib in patients who may have increased cardiac risk 
factors or prior cardiac events, information on cardiac toxici-
ties, including heart failure and cardiomyopathy, associated 
with sunitinib therapy is accumulating (Table 3). In the 
pivotal phase III study of sunitinib in RCC, 10% of patients 
experienced a decline in ejection fraction, with most changes 
being grade 1 or 2 and not dose limiting.14 It is important 
to note that these patients were prescreened (with inclu-
sion criteria of left ventricular ejection fraction of greater 
than or equal to the lower limit of normal) and those who 
had cardiac dysfunction, deﬁ  ned as myocardial infarction, 
unstable angina, coronary or peripheral artery bypass graft, 
symptomatic congestive heart failure, transient ischemic 
attack, cerebrovascular accident or pulmonary edema within 
the past 12 months, were excluded from participation. Other 
cardiac adverse event data come from experience with suni-
tinib in patients with gastrointestinal stromal tumors (GIST) 
in which 11% patients had cardiovascular events including 
myocardial infarction or congestive heart failure.27 In this 
phase I/II study of patients with GIST, reductions of at least 
10% in ejection fraction occurred in 28% patients treated with 
sunitinib. A separate retrospective review of 224 patients 
receiving sunitinib for 10 different malignancies identiﬁ  ed 
6 patients (3%), 4 of whom had RCC, who developed clini-
cally signiﬁ  cant congestive heart failure.28
An observational study of sunitinib or sorafenib, another 
multi-targeted tyrosine kinase inhibitor, for treatment of 
metastatic RCC identiﬁ  ed 34% of patients as having a cardiac 
event, deﬁ  ned as increased cardiac enzymes (both symptom-
atic and asymptomatic), symptomatic arrhythmia, left ven-
tricular dysfunction, or acute coronary syndrome, and 41% 
having electrocardiogram (ECG) changes.29 The investigators 
Table 3 Studies reporting cardiovascular side effects in patients treated with sunitinib
Author Motzer14 Chu27 Khakoo28 Telli42 Schmidiger29a
Study design Prospective Retrospective Retrospective Retrospective 10 retrospective 
64 prospective
Number of patients 375 75 224 48 74
% of patients with 
mRCC
100% 0% (100% GIST) 77% (23% other 
solid tumors)
85% (15% GIST) 100%
Pre-existing HTNb NR 29% 54% 50% 52%
Prior CAD N/A 5% 13% 6% 9%
Prior CHF or 
cardiomyopathyc
N/A 0% NR 6% 7%
HTN during therapyd 24% 47% NR 67% NR
10% ejection fraction 
decline
8% 28% 3%e 15% 14%
Symptomatic CHF 2% 8% 3% 15%f NR
aStudy included sunitinib and sorafenib.
bHypertension not deﬁ  ned in most studies, Chu27 deﬁ  ned hypertension as systolic 150 mmHg or diastolic 100 mmHg.
cCHF or cardiomyopathy deﬁ  ned as prior symptomatic heart failure or ejection fraction below lower limit of normal.
dPatients on therapy who had hypertension (includes pre-existing and on treatment) as determined by each study.
eStudy reported patients with symptomatic CHF, all of whom had 10% ejection fraction decline with therapy. Additional patients with 10% decline in ejection fraction 
without development of symptomatic CHF were not clearly deﬁ  ned.
fStudy identiﬁ  ed patients at the time of presentation with grade 3/4 left ventricular dysfunction (ejection fraction  40%) and symptomatic CHF requiring intervention.
Abbreviations: GIST, gastrointestinal stromal tumors; RCC, renal cell carcinoma; HTN, hypertension; CAD, coronary artery disease; CHF, congestive heart failure; N/A, not 
included if within past year; NR, not reported.OncoTargets and Therapy 2009:2 56
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prospectively evaluated 74 patients receiving sunitinib or 
sorafenib for mRCC with cardiac enzymes drawn with routine 
blood sampling bimonthly and performed ECGs monthly 
in asymptomatic patients and at any time patients clinically 
appeared to have cardiac symptoms. Thirteen of the 25 
patients with a cardiac event had cardiac symptoms, deﬁ  ned 
as dyspnea on exertion, angina, or dizziness. Cardiac enzymes 
drawn with routine bloodwork or at the time of cardiac 
symptoms were elevated in 21 patients; 12 of these patients 
with elevated cardiac enzymes had no clinical symptoms. 
Of these asymptomatic patients with elevated cardiac 
enzymes, some underwent dose reduction or discontinuation, 
with subsequent resolution of enzymes. Other patients, 
showed ﬂ  uctuations of cardiac enzymes which were felt 
to be related to the cyclic nature of sunitinib dosing. ECG 
changes were found in 12 of 25 symptomatic patients and 
in 18 (24%) asymptomatic patients. All patients recovered 
after cardiac medical event management and were considered 
eligible for reinitiation of TKI therapy. While ECGs are 
generally recommended at the time clinical concerns for 
cardiac symptoms arise, the signiﬁ  cance of screening for 
asymptomatic ECG changes is unclear at this time.
It is important to assess a patient’s cardiac risk factors 
and cardiovascular history, and if concern for heart failure is 
identiﬁ  ed, to obtain appropriate cardiac studies and monitor 
closely for changes in symptoms or functional decline with 
repeat cardiac evaluation. Congestive heart failure and left 
ventricular dysfunction generally, though not always, are 
reversible after discontinuation of sunitinib. Thus patient 
education and clinical vigilance are paramount to ensure early 
identiﬁ  cation of symptoms with timely clinical assessment 
and appropriate laboratory and cardiac evaluation in order 
to initiate aggressive medical intervention when clinically 
indicated.
Most studies have demonstrated sunitinib-induced 
increases in mean systolic and diastolic blood pressure, 
with variable incidences of hypertension ranging from 28% 
to 47% reported in studies.14,16,27 Blood pressure should be 
evaluated as part of toxicity reviews and patients should be 
instructed to perform daily home blood pressure monitoring. 
Standard lifestyle recommendations for hypertension should 
be followed including regular exercise, weight control, and 
sodium restriction. Pharmacologic interventions include most 
classes of antihypertensives and no speciﬁ  c class has been 
proven more effective for sunitinib-induced hypertension. 
The non-dihydropyridine calcium channel blockers, vera-
pamil and diltiazem, are both metabolized by the CYP3A4 
cytochrome and should be used with caution. Patients should 
be given instructions regarding systolic and diastolic blood 
pressure parameters, for example systolic blood pressure 
greater than 150 or diastolic blood pressure greater than 
90, which would necessitate notiﬁ  cation of their oncology 
health care team. Sunitinib induced hypertension is usually 
reversible and improves with discontinuation, thus it is 
important to review antihypertensive medications and make 
appropriate adjustments if sunitinib regimen is reduced or 
treatment is interrupted. Additionally, blood pressure should 
be monitored during the scheduled 2 weeks off sunitinib in 
each cycle as improvements in blood pressure may require 
a temporary decrease in antihypertensive therapy.
Sunitinib can cause QT prolongation and should be given 
with caution in patients with history of QT prolongation or 
taking other medications which can prolong the QT interval. 
Medications affecting the QT interval include, but are not 
limited to, antiarrhythmics, antipsychotics, some antidepres-
sants, certain antibiotics, some antiemetics, and methadone. 
Baseline electrocardiograms should be obtained in patients 
with relevant history or symptoms of arrhythmia. These 
patients should then be monitored with repeat ECG in each 
cycle of therapy and in whom clinical symptoms develop.
Gastrointestinal toxicity
Patients on sunitinib may experience anorexia, dyspepsia, 
ﬂ  atulence, bloating, nausea or vomiting, most often mild to 
moderate in severity. Appropriate intervention with dietary 
changes such as avoidance of irritating or spicy foods 
and increasing the frequency of small meals may provide 
improvement of symptoms. Pharmacologic intervention 
with antiemetics or proton pump inhibitors as needed to 
avoid decreased oral intake. Initial patient education should 
place emphasis on the importance of maximizing oral hydra-
tion strategies to avoid dehydration and the potential for 
therapy interruption. Patients and family members should be 
instructed to call the ofﬁ  ce if they develop lightheadedness 
or dizziness or a decrease in blood pressure, allowing early 
assessment and intervention for dehydration with intravenous 
hydration.
Oral changes include taste alterations, mouth sensitivity, 
and functional and clinical stomatitis. These toxicities are 
usually grade 2 or less and are experienced by up to 30% of 
patients. In general, the oral toxicities increase throughout 
the active drug period of each cycle and improve during 
the 2 week off period. Oral care changes should include 
gentle brushing of teeth with toothpaste and mouthwash 
which are non-alcohol based, such as pediatric toothpaste 
(Table 4). Symptomatic relief can be tailored to symptoms OncoTargets and Therapy 2009:2 57
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such as special mouthwash preparations containing viscous 
lidocaine for mucositis, or lip balm for cheilitis. If necessary, 
pain medication may be needed to prevent dysphagia and 
decrease risk of dehydration or malnutrition. For grade 3 
and 4 mucositis, interruption in therapy or dose reduction 
should be considered to prevent clinical deterioration in 
nutritional status.
Approximately half of sunitinib-treated patients with meta-
static RCC experience diarrhea, usually grade 1 or 2 which is 
deﬁ  ned as an increase of up to 6 stools a day and/or requirement 
of less than 24 hours of intravenous hydration secondary to 
diarrhea.14 Diarrhea is usually characterized as loose, but not 
watery, and associated with urgency. Management of symptoms 
of diarrhea includes attention to dietary intake and avoidance of 
aggravating factors which can contribute to diarrhea. Aggres-
sive oral ﬂ  uid intake should be encouraged to avoid dehydra-
tion. Bananas, rice, and ﬁ  ber-containing foods are among the 
dietary additions which can be recommended for patients. 
Pharmaceutical management options include loperamide or 
diphenoxylate. Patients should be encouraged to initiate these 
medications at the ﬁ  rst signs of diarrhea. If diarrhea is severe 
and worsened with eating, loperamide or diphenoxylate can 
be taken 30 minutes prior to a meal. Cholestyramine taken 
prior to meals provides another alternative treatment option. 
Early intravenous hydration may be indicated for patients who 
develop dehydration from inadequately controlled diarrhea, 
and may minimize the need for treatment interruption or dose 
reduction. Detailed review with patient regarding adherence 
to recommended anti-diarrheal agent regimen for control of 
diarrhea is important to determine if changes in medications 
or dosing guidelines should be made.
Dermatologic changes
Skin and hair changes are frequent in patients taking 
sunitinib. The constellation of dermatological changes is 
unique and the management of side effects has largely 
been based on expert opinion and clinical experience. 
Palmar plantar erythrodysesthesia, also known as HFS, is 
a dermatologic condition which involves painful blister and 
callus formation of areas which are subjected to pressure or 
friction, such as the palms, thumbs and ﬁ  ngers, and soles 
of feet (Figures 1 and 2).30–32 Patients may also experience 
severe dry skin, cracking, and desquamation. The severity 
of the painful calluses can interfere with the patient’s abil-
ity to maintain their normal schedule of activities and lead 
to a decline in function and quality of life; in severe cases, 
patients are unable to bear weight on their feet secondary 
to pain. Hand-foot symptoms usually improve during the 
2 week off drug period during each cycle; however, grade 3 
HFS (pain interfering with activities of daily living) requires 
dose delays and possibly dose reductions. Patients should 
wear comfortable shoes with extra support. Management 
of acral erythema includes creams, lotion, and pedicure. 
Rashes may develop on any body surface and may be macu-
lar or papular in appearance. Pruritis may occur with dry 
skin and is managed by providing aggressive symptomatic 
relief with topical emollients or steroids, as well as consid-
eration or oral antihistamine (Table 5). Hyperkeratosis can 
be treated with urea-based creams. Cotton socks, gel insole 
liners, and shoes designed for extra comfort and cushion 
may minimize the extent and severity of hand foot syndrome 
for some patients. Effective management of dermatologic 
toxicities can improve tolerance and often symptoms do 
not recur following resolution of dermatologic reaction. 
Emphasis on initiation of skin care at ﬁ  rst signs of derma-
tologic toxicity and early notiﬁ  cation of oncology health 
care team will allow assessment and changes to clinical 
regimen as indicated.
Sunitinib commonly results in a yellowish color of 
patient’s skin which is related to this drug. Color changes 
can also be seen in the urine. These color changes can be 
confused with jaundice, but are not related to elevated 
bilirubin as evidenced by lack of yellow conjunctivae. Hair 
Table 4 Oral care products
Cleansers and rinses Product information
  Salt water rinse
  Salt and baking soda rinse
 Biotine® rinse Bioactive enzymes
  Chlorhexidine gluconate 0.12% Antimicrobial mouth rinse
Toothpastes
 Sensodyne® toothpaste Potassium nitrate to reduce 
painful sensitivity
  Children’s toothpaste Flavoring is milder and burns less
Rinses for comfort 
and mucosal protection
 RincinolTM PRN Aloe vera rinse
   Gelclair® bioadherent oral gel Hydrates, soothes, and protects 
oral mucosa
  Lidocaine Viscous 2% lidocaine hydrocholoride 
solution
Lip protectants
 Blistex® Dimethicone
 Burt’s  Bees® Beeswax, oils, lanolin
 Carmex® Menthol, camphor, phenol
  Zim’s Crack Creme® ArnicaOncoTargets and Therapy 2009:2 58
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discoloration involves depigmentation and a resulting grayish 
hair color which reverses after discontinuation of sunitinib. 
Asymptomatic subungual hemorrhages occasionally occur 
with sunitinib, but do not require any intervention or change 
in treatment plan.
Toxicity in patients with brain 
metastases
As previously discussed, initial studies of sunitinib in RCC 
excluded prior or current brain metastases. Subsequently, 
with expanded access and increasing use of sunitinib in 
the community, the use of sunitinib in patients with brain 
metastases has increased. A few retrospective analyses have 
reviewed the outcomes of patients with metastatic RCC 
involving brain metastases undergoing targeted therapy 
treatment. The incidence of intracranial bleeding or hemor-
rhage in these studies with sunitinib or sorafenib ranged 
between 0% and 7%.33,43 The importance of blood pressure 
control was highlighted in a retrospective series which 
reported a 7% incidence of intracerebral hemorrhage; 80% 
of these patients had uncontrolled hypertension at the time 
of diagnosis.33 While most brain metastases pretreated with 
surgical resection or radiotherapy prior to sunitinib therapy 
did not result in any adverse intracranial bleeding events, 
close clinical observation and good blood pressure control 
are recommended. Sunitinib therapy may be held for several 
days prior to and following palliative radiation therapy to 
minimize overlapping toxicities.
Posterior reversible 
leukoencephalopathy syndrome
Posterior reversible leukoencephalopathy syndrome (PRES) 
has been reported in a patient with RCC 2 weeks after starting 
the ﬁ  rst cycle of treatment at 50 mg daily.35 PRES is charac-
terized by acute hypertension, seizures, impaired vision, and 
classic ﬁ  ndings on MRI or CT imaging of the brain. As in 
the reported case, PRES is reversible, if diagnosed early in 
the course and treated with discontinuation of sunitinib and 
appropriate control of hypertension and seizures.
Tumor lysis syndrome
As evidenced by sunitinib’s efﬁ  cacy in producing robust 
overall response rates, large bulky tumors may respond 
dramatically to treatment and tumor lysis syndrome has 
Figure 1 Grade 3 hand-foot syndrome including acral erythema, hyperkeratotic areas, and desquamation. Considered grade 3 due to pain interfering with function.OncoTargets and Therapy 2009:2 59
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been reported as a rare complication. Prophylaxis should be 
considered in those patients who may be at risk.36
Hematologic toxicity
In the initial phase III trial comparing sunitinib with interferon-
alpha, all grade leukopenia, neutropenia, anemia, and 
thrombocytopenia occurred in 60% to 70% of all patients treated 
with sunitinib.14 According to the expanded access analysis, in 
patients on sunitinib for 6 months or longer, transient grade 3 
or 4 neutropenia and thrombocytopenia occurred in less than 
6% and 8% of patients, respectively.16 Despite reductions in 
absolute neutrophil count, neutropenic fever or infection was 
not reported in the phase II or phase III trials.12–14,37 Less than 
4% of patients experience grade 3 or 4 toxicity.14 Interestingly, 
macrocytosis has been observed in some patients but was 
not associated with decreased folate or cobalamin levels and 
improved in patients after discontinuation of sunitinib.38 Blood 
counts usually recover during the 2 week off period or with 
drug interruptions. Complete blood counts should be obtained 
immediately prior to each cycle in patients with documented 
cytopenias in prior cycles or at the end of the 4-week dosing 
period when cytopenias are likely to nadir. If grade 3 or 4 
neutropenia or thrombocytopenia are present at the time of 
initiation of a new cycle, dose delay is recommended until toxic-
ity is grade 2 or less. If the same toxicity occurs in subsequent 
cycles, dose reduction in sunitinib should be considered.
The same antiangiogenesis effect that contributes to the 
potency of sunitinib by preventing adequate blood ﬂ  ow to 
malignant tumors, also leads to the potential for signiﬁ  cant 
adverse events by preventing adequate blood ﬂ  ow to normal 
tissues at a time of injury. Bleeding has been noted in the 
form of epistaxis, gingival, or gastrointestinal bleeding.14 
The use of saline nasal spray and a bedside humidiﬁ  er may 
reduce the incidence and severity of dryness in nasal passages 
resulting in risk of epistaxis.
Theoretically, patients on angiogenesis inhibitors are at risk 
of poor surgical wound healing, and sunitinib should be held in 
the perioperative period. The half-life of sunitinib is 40 hours, 
thus discontinuation of sunitinib for 1 week, or approximately 
5 half-lives, prior to major surgical procedures would allow 
time for adequate drug elimination in order to prevent interfer-
ence with angiogenesis, hemostasis, and wound healing.
Secondary to the increased risks of bleeding and poor 
wound healing, the use of anticoagulants may compound 
Figure 2 Grade 2 hand-foot syndrome including erythema, desquamation, and skin discoloration. Considered grade 2 because mild discomfort did not interfere with function.OncoTargets and Therapy 2009:2 60
Schwandt et al
bleeding risks and potential complications when combined 
with sunitinib therapy. Coumadin should be used with cau-
tion in patients on sunitinib due prolonged effect on the 
coagulation cascade. As mentioned previously, coumadin 
also undergoes metabolism primarily by the hepatic P450 
enzyme and thus the interaction of sunitinib can potentially 
alter levels of both drugs.39 Since most patients on sunitinib 
therapy are administered cycles of 4 weeks of sunitinib and 
2 weeks without sunitinib, this planned alternation in therapy 
can lead to variability in coumadin metabolism and requires 
close attention to the potential for alterations in INR levels.
Conclusion
Since the approval of sunitinib for advanced RCC, there 
has been a fundamental shift in the management of patients 
with kidney cancer. In many ways, the breakthroughs in the 
understanding of the mechanisms of RCC and its targeted 
treatment options provide a model system to understand 
the future of cancer care. The shifting paradigm of cancer 
treatment no longer solely relies on intermittent physician-
directed administration of therapy in a healthcare facility; 
instead, it increasingly entails the management of patients 
self-administering potent oral daily medication. Maximizing 
clinical outcomes of sunitinib therapy requires clear, 
effective communication, anticipation of side effects, and 
early intervention to avoid treatment delays and dose-limiting 
toxicities.
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Table 5 Skin care products for hand-foot syndrome
Skin care products Product information
Cetaphil skin cleanser,   Aveeno® shower gel Non-deodorant, non-fragrant body washes
Udderly Smooth® udder cream Allantoin, dimethicone
Udderly Smooth® extra care cream Allantoin, dimethicone, 10% urea
Aveeno® skin relief moisturizing cream Natural colloidal oatmeal; dimethicone
Norwegian Formula: soothing relief anti-itch 
moisturizer by Neutrogena
Dimethicone 1%, camphor 0.1%, and lidocaine
Norwegian Formula: foot cream by Neutrogena Ceterayl alcohol, dimethicone, menthol and urea
Bag Balm® 8-hydroxyquinoline sulfate 0.3% in a petrolatum lanolin base; eucalyptus
Eucerin® cream Mineral oil, lanolin
Eucerin® dry skin therapy Urea and alpha hydroxy acid
Aquaphor® healing ointment 41% petrolatum
Xenaderm® ointment Balsam peru, castor oil, trypsin
Corn Huskers Lotion® Calcium alginate; non-oily moisturizer
Biaﬁ  ne® cream Water-based emulsion for radiation dermatitis or abrasions
Gold Bond® triple action relief cream 5% dimethicone, 0.15% menthol, aloe, vitamin E
Gold Bond® ultimate healing lotion 5% dimethicone, jojoba esters, aloe
Gold Bond® anti-itch cream 1% pramoxine HCL, 1% menthol
KerasalTM 5% salicylic acid: softens skin 10% urea: exfoliates and moisturizes
KeralacTM cream 50% urea: exfoliates and moisturizes vitamin E, lactic acid, zinc
KeralacTM lotion 35% urea: exfoliates and moisturizes vitamin E, lactic acid, zinc
Carmol® 40 40% urea
Miracle Foot Repair® cream 60% aloe, 0.1% menthol
Regenecare® HA 2% lidocaine, humectanct (moisturizer), aloe vera extract, 
hyaluronic acid (anti-inﬂ  ammatory agent)
Lidocaine topical 2% lidocaine
Lidamantle® 3% lidocaine HCL
Lidamantle HC® 3% lidocaine HCL, 0.5% hydrocortisone acetate
Pramocaine HCL 1% pramoxine hydrochloride
Tetracaine jelly 2% lidocaineOncoTargets and Therapy 2009:2 61
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